home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Arsenal Files 6
/
The Arsenal Files 6 (Arsenal Computer).ISO
/
health
/
med9603.zip
/
M9630470.TXT
< prev
next >
Wrap
Text File
|
1996-02-27
|
2KB
|
32 lines
Document 0470
DOCN M9630470
TI Self-sufficiency and blood transmitted diseases.
DT 9603
AU Glomstein A; Institute for Haemophilia, Oslo, Norway.
SO Blood Coagul Fibrinolysis. 1995 Jul;6 Suppl 2:S23-6. Unique Identifier :
AIDSLINE MED/96076194
AB The Council of Europe and the EEC Council of Ministers have strongly
promoted self-sufficiency for plasma products on the basis of voluntary
non-remunerated donors. Several European countries have a programme of
self-sufficiency with plasma products, either with national
fractionation plants (e.g. Belgium, Finland) or based on contract
fractionation (e.g. Norway, Slovenia). Advantages of national
self-sufficiency includes epidemiological factors, economical factors
and also ethical and moral issues. Self-sufficiency is one of the basic
conditions for reducing the hazard of transmission of infectious
diseases. Norway has been self-sufficient with coagulation factors since
1981. Price mechanisms and market forces have been important factors in
ensuring the necessary plasma volume, and fractionation methods
rendering high yields of factor VIII are initially preferred. This
policy has resulted in a low prevalence of antibodies against human
immunodeficiency virus (6%), hepatitis B virus (28%) and hepatitis C
virus (41%). No Norwegian haemophiliacs have been infected with
hepatitis A through FVIII concentrates.
DE *Blood Banks *Blood Donors Blood Transfusion/*ADVERSE EFFECTS
European Economic Community Human Norway Virus Diseases/*TRANSMISSION
JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).